Steven J. Schnelle joins the IDN Summit to discuss pricing legislation, administrative actions and new entrants to the drug and manufacturing market. Steven’s panel will uncover the potential far-reaching implications of complex changes to drug pricing as legislatures and regulators strive to lower prices and out-of-pocket costs for patients through greater transparency in drug prices and rebates.

Learn more and register here.